Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.74
+1.3%		$0.84
$0.54
▼
$2.13
$203.68M0.245.07 million shs4.52 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$4.32
+3.0%		$4.16
$2.54
▼
$7.18
$818.04M1.433.03 million shs1.74 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$12.98
-0.3%		$24.13
$11.36
▼
$35.83
$640.78M1.66733,765 shs377,027 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.59
+5.9%		$2.98
$2.22
▼
$5.49
$773.85M2.33.17 million shs1.16 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+2.46%+9.90%-16.09%-43.74%-65.76%
Annexon, Inc. stock logo
ANNX
Annexon
+6.35%+11.44%0.00%-21.97%+32.18%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-2.47%-15.45%-53.94%-57.46%-26.02%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
+1.67%-1.21%-15.57%-30.48%-46.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.74
+1.3%		$0.84
$0.54
▼
$2.13
$203.68M0.245.07 million shs4.52 million shs
Annexon, Inc. stock logo
ANNX
Annexon
$4.32
+3.0%		$4.16
$2.54
▼
$7.18
$818.04M1.433.03 million shs1.74 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$12.98
-0.3%		$24.13
$11.36
▼
$35.83
$640.78M1.66733,765 shs377,027 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.59
+5.9%		$2.98
$2.22
▼
$5.49
$773.85M2.33.17 million shs1.16 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+2.46%+9.90%-16.09%-43.74%-65.76%
Annexon, Inc. stock logo
ANNX
Annexon
+6.35%+11.44%0.00%-21.97%+32.18%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-2.47%-15.45%-53.94%-57.46%-26.02%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
+1.67%-1.21%-15.57%-30.48%-46.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.43
Hold$3.90430.61% Upside
Annexon, Inc. stock logo
ANNX
Annexon
2.40
Hold$15.29254.25% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.73
Moderate Buy$24.5689.18% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.75
Moderate Buy$9.60271.37% Upside

Current Analyst Ratings Breakdown

Latest AKBA, SANA, ANNX, and AVBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/27/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$18.00 ➝ $30.00
10/26/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$21.00
10/26/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$25.00
10/21/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/20/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$45.00 ➝ $29.00
10/16/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$29.00
10/15/2026
Annexon, Inc. stock logo
ANNX
Annexon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/8/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$47.00 ➝ $27.00
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$45.00 ➝ $18.00
10/7/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$42.00 ➝ $29.00
(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M0.86N/AN/A$0.12 per share6.13
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.42 per shareN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.11N/AN/AN/A-13.54%-88.88%-7.74%11/5/2026 (Estimated)
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%11/9/2026 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%11/16/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.76N/AN/AN/AN/A-103.02%-39.16%11/5/2026 (Estimated)

Latest AKBA, SANA, ANNX, and AVBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$1.04N/AN/AN/A$0.80 millionN/A
11/9/2026Q3 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.28N/AN/AN/A$3.50 millionN/A
11/5/2026Q3 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.0360N/AN/AN/A$46.94 millionN/A
11/5/2026Q3 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1478N/AN/AN/AN/AN/A
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/10/2026Q2 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1469-$0.13+$0.0169-$0.22N/AN/A
8/5/2026Q2 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.0420-$0.02+$0.0220-$0.03$48.85 million$49.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.99
1.43
1.35
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
5.53
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Annexon, Inc. stock logo
ANNX
Annexon
N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
194277.11 million265.19 millionOptionable
Annexon, Inc. stock logo
ANNX
Annexon
92189.58 million170.03 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7749.31 million45.08 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
142299.36 million223.32 millionOptionable

Recent News About These Companies

Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
November 4 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-sana-biotechnology-inc-nasdaq-sana-stock-now-rated-moderate-buy-by-sell-side-analysts-2026-11-04/
Sana Biotechnology, Inc. (SANA) Analyst Insights, Price Targets & Recommendations - Yahoo Finance
November 3 at 8:32 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SANA/analyst-insights/
Sana Biotechnology (SANA) Projected to Announce Quarterly Earnings on Thursday
October 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-sana-biotechnology-sana-projected-to-announce-quarterly-earnings-on-thursday-2026-10-29/
Sana Biotechnology (NASDAQ:SANA) Sets New 1-Year Low - Here's What Happened
October 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-sets-new-1-year-low-heres-what-happened-2026-10-19/
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.7% - What's Next?
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-stock-price-down-67-whats-next-2026-10-13/
Sana Biotechnology: A Shot At Diabetes
October 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4953698-sana-biotechnology-a-shot-at-diabetes
Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low - Should You Sell?
October 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-hits-new-52-week-low-should-you-sell-2026-10-12/
Sana Biotechnology, Inc. (SANA) - What Are Analysts Thinking About This Stock?
October 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-sana-biotechnology-inc-sana-what-are-analysts-thinking-about-this-stock-2026-10-10/
Sana Biotechnology, Inc. Common Stock
October 9, 2026  |  fxempire.comF
Sana Biotechnology (NASDAQ:SANA) Shares Up 3.1% - Here's Why
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-up-31-heres-why-2026-10-07/
6 'moonshot' biotech stocks that offer big risks, bigger rewards
September 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards/ar-AA2cNIJ1
Sana Biotechnology (SANA)
September 23, 2026  |  es.investing.comhttps://es.investing.com/equities/sana-biotechnology
Sana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949033-sana-biotechnology-inc-sana-presents-at-h-c-wainwright-28th-annual-global-investment
Sana Biotechnology op Morgan Stanley conferentie: focus op diabetes
September 15, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/sana-biotechnology-op-morgan-stanley-conferentie-focus-op-diabetes-93CH-914514
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946244-sana-biotechnology-inc-sana-presents-at-morgan-stanley-24th-annual-global-healthcare
Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3556440
Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3561461
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945241-sana-biotechnology-inc-sana-presents-at-citigroups-biopharma-back-to-school-summit-2026
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945095-sana-biotechnology-inc-sana-presents-at-wells-fargo-21st-annual-healthcare-conference
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
September 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-sana-biotechnology-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302870954.html
Sana Biotechnology to Present at September 2026 Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354578/0/en/sana-biotechnology-to-present-at-september-2026-investor-conferences.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$0.74 +0.01 (+1.27%)
As of 12:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Annexon stock logo

Annexon NASDAQ:ANNX

$4.32 +0.13 (+2.98%)
As of 12:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$12.98 -0.04 (-0.31%)
As of 12:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$2.58 +0.15 (+5.94%)
As of 12:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas